In vivo Cell Therapy

RNA-Driven Cellular Reprogramming In Vivo

Enabling targeted in vivo cell reprogramming for next-generation therapies.
In vivo cell therapy leverages non-viral, nucleic acid-based approaches to engineer cells directly within the body.

Crystal NAX supports this emerging modality through intelligent design CAR encoding RNA and/or accessory genes to boost therapeutic activity, ligand bio-conjugation service,development of next-generation targeted LNP, and robust functional characterization. Our platform supports the development of in-vivo RNA-based applications that enable controlled, transient, and tissue-specific cellular modulation

Key Capabilities

  • RNA design for transient expression and controlled activity
  • Support for diverse functional payloads
  • Optimization for in vivo performance
  •  LNP systems designed for cell- and tissue-specific delivery
  • Surface-functionalized nanoparticles for enhanced targeting
  • Rapid screening of delivery performance in vivo
  •  Analytical assessment of RNA and LNP properties
  • Functional evaluation of cellular responses
  • Data-driven refinement of in vivo cell therapy strategies

Related Services